With the $1.95bn acquisition of Alder (~100% premium), Lundbeck is set to enter (with Eptinezumab) the fast-growing and highly-competitive $4bn migraine space. While the deal would be margin-dilutive in the short term, given higher commercial expenses, the blockbuster potential of Eptinezumab would ensure EPS accretion from 2023. With $3bn still in the bag, another acquisition might be on the cards but, before that happens, the new CEO needs to prove her integration and commercial execution c
18 Sep 2019
Alder’s acquisition reduces Lundbeck’s headache
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Alder’s acquisition reduces Lundbeck’s headache
H. Lundbeck A/S Class B (LUNB:WBO) | 0 0 0.0%
- Published:
18 Sep 2019 -
Author:
Rishabh Kochar -
Pages:
3
With the $1.95bn acquisition of Alder (~100% premium), Lundbeck is set to enter (with Eptinezumab) the fast-growing and highly-competitive $4bn migraine space. While the deal would be margin-dilutive in the short term, given higher commercial expenses, the blockbuster potential of Eptinezumab would ensure EPS accretion from 2023. With $3bn still in the bag, another acquisition might be on the cards but, before that happens, the new CEO needs to prove her integration and commercial execution c